Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013194 | 0.95 | HPGD (0.44) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL9259815 | 0.94 | HPGD (0.43) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL709348 | 0.92 | HPGD (0.45) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL9614726 | 0.89 | HPGD (0.40) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL9564059 | 0.79 | HPGD (0.45) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL9563923 | 0.77 | ALDH1A1 (0.43) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL9257402 | 0.77 | — | — | |
| SCHEMBL7045870 | 0.77 | HPGD (0.43) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL3060111 | 0.76 | HPGD (0.42) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL9563934 | 0.74 | HPGD (0.41) | HPGDALDH1A1SMN1; SMN2RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923537-B1 | PROCESS FOR THE PREPARATION OF CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2001-10-31 | — | — | EP | claimed |
| US-8066970-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-8066970-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-8066970-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-20090098059-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-04-16 | — | — | US | disclosed |
| US-20070264201-A1 | Contrast Agents | GE HEALTHCARE LIMITED (NO) | 2007-11-15 | — | — | US | disclosed |
| US-20070264201-A1 | Contrast Agents | GE HEALTHCARE LIMITED (NO) | 2007-11-15 | — | — | US | disclosed |
| US-20070264201-A1 | Contrast Agents | GE HEALTHCARE LIMITED (NO) | 2007-11-15 | — | — | US | disclosed |
| EP-0923537-B1 | PROCESS FOR THE PREPARATION OF CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2001-10-31 | — | — | EP | disclosed |
| EP-0160036-A4 | NOVEL SYNTHETIC METHODS FOR NON-IONIC RADIOGRAPHIC CONTRAST MEDIA. | BIOPHYSICA FOUNDATION (US) | 1987-06-11 | — | — | EP | disclosed |
| EP-0160036-A1 | NOVEL SYNTHETIC METHODS FOR NON-IONIC RADIOGRAPHIC CONTRAST MEDIA | BIOPHYSICA FOUNDATION (US) | 1985-11-06 | — | — | EP | disclosed |
| WO-1985001727-A1 | NOVEL SYNTHETIC METHODS FOR NON-IONIC RADIOGRAPHIC CONTRAST MEDIA | BIOPHYSICA FOUNDATION (US) | 1985-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098059-A1 | CONTRAST AGENTS | IPO4, IPO11, IPO8 | HPGD 2630/4885ALDH1A1 4130/4885SMN1; SMN2 4565/4885 |
| US-20070264201-A1 | Contrast Agents | TPO, IPO4, IPO11 | HPGD 2130/4885ALDH1A1 3300/4885SMN1; SMN2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.